[OncotypeDX in breast cancer]

Luxardo R, Garcia Marti S, Lazo E, Alfie V, Ciapponi A, Augustovski F, Bardach A, Alcaraz A, Pichon Riviere A
Record ID 32018004427
Original Title: OncotypeDX en cáncer de mama
Authors' recommendations: Moderate-quality evidence shows that OncotypeDX® probably provides a significant net benefit in patients with HR+/HER2- early breast cancer and with intermediate risk of distant recurrence, given its performance in predicting chemotherapy benefits. The clinical practice guidelines consulted suggest using OncotypeDX® as one of the genetic test options in patients where indication for adjuvant chemotherapy is uncertain. United States, France, Germany and United Kingdom health funders cover OncotypeDX®. The Latin American and Argentinian health funders do not mention this technology. The United Kingdom considers this technology to be cost-effective, as any of the other genetic tests available. No local economic evaluations on the cost-effectiveness of OncotypeDX® have been found.
Project Status: Completed
Year Published: 2022
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Breast Neoplasms
  • Genetic Testing
  • Chemotherapy, Adjuvant
  • Biomarkers, Tumor
  • Neoplasm Recurrence, Local
  • Prognosis
  • Gene Expression Profiling
  • Receptors, Estrogen
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.